Oruka Therapeutics (ORKA) Income towards Parent Company (2010 - 2024)
Oruka Therapeutics' quarterly Income towards Parent Company came in at -$2.7 million in Q2 2024, down 80.95% year-on-year from -$14.1 million in Q3 2023, and down 33.3% quarter-over-quarter from -$2.0 million in Q1 2024.
Oruka Therapeutics has reported Income towards Parent Company for 15 years, with the latest figure at -$2.7 million in Q2 2024.
- For the quarter ending Q2 2024, Income towards Parent Company fell 80.95% year-over-year to -$2.7 million; the trailing twelve-month figure through Mar 2025 stood at -$2.7 million (up 55.38% YoY), and the FY2023 full-year result was -$5.3 million, up 46.21% from the prior year.
- Income towards Parent Company for Q2 2024 stood at -$2.7 million, down from -$2.0 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$1.1 million in Q4 2023, with the low at -$5.7 million in Q4 2021.
- Average Income towards Parent Company over 5 years is -$2.7 million, with a median of -$2.2 million recorded in 2022.
- Year-over-year, Income towards Parent Company tumbled 318.03% in 2020 and soared 79.32% in 2022.
- Tracing ORKA's Income towards Parent Company over 5 years: stood at -$5.1 million in 2020, then retreated by 10.75% to -$5.7 million in 2021, then soared by 79.32% to -$1.2 million in 2022, then rose by 7.24% to -$1.1 million in 2023, then slumped by 145.91% to -$2.7 million in 2024.
- The last three Income towards Parent Company figures came in at -$2.7 million (Q2 2024), -$2.0 million (Q1 2024), and -$1.1 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -2.68 Mn |
| Mar 31, 2024 | -2.01 Mn |
| Dec 31, 2023 | -1.09 Mn |
| Sep 30, 2023 | -1.42 Mn |
| Jun 30, 2023 | -1.48 Mn |
| Mar 31, 2023 | -1.35 Mn |
| Dec 31, 2022 | -1.17 Mn |
| Sep 30, 2022 | -2.33 Mn |
| Jun 30, 2022 | -3.15 Mn |
| Mar 31, 2022 | -3.27 Mn |
| Dec 31, 2021 | -5.68 Mn |
| Sep 30, 2021 | -4.71 Mn |
| Jun 30, 2021 | -4.83 Mn |
| Mar 31, 2021 | -4.10 Mn |
| Dec 31, 2020 | -5.13 Mn |
| Sep 30, 2020 | -1.99 Mn |
| Jun 30, 2020 | -1.30 Mn |
| Mar 31, 2020 | -1.32 Mn |
| Dec 31, 2019 | -1.23 Mn |
| Sep 30, 2019 | -1.16 Mn |
| Jun 30, 2019 | -1.44 Mn |
| Mar 31, 2019 | -1.66 Mn |
| Dec 31, 2018 | -1.49 Mn |
| Sep 30, 2018 | -1.59 Mn |
| Jun 30, 2018 | -2.12 Mn |
| Mar 31, 2018 | -2.74 Mn |
| Dec 31, 2017 | -4.26 Mn |
| Sep 30, 2017 | -4.43 Mn |
| Jun 30, 2017 | -5.52 Mn |
| Mar 31, 2017 | -4.34 Mn |
| Dec 31, 2016 | -4.24 Mn |
| Sep 30, 2016 | -4.66 Mn |
| Jun 30, 2016 | -3.89 Mn |
| Mar 31, 2016 | -3.65 Mn |
| Dec 31, 2015 | -3.17 Mn |
| Sep 30, 2015 | -2.81 Mn |
| Jun 30, 2015 | -2.72 Mn |
| Mar 31, 2015 | -2.74 Mn |
| Dec 31, 2014 | -2.61 Mn |
| Sep 30, 2014 | -2.28 Mn |
| Jun 30, 2014 | -2.41 Mn |
| Mar 31, 2014 | -2.39 Mn |
| Dec 31, 2013 | -2.95 Mn |
| Sep 30, 2013 | -1.72 Mn |
| Jun 30, 2013 | -1.20 Mn |
| Mar 31, 2013 | -1.07 Mn |
| Dec 31, 2012 | -840,000.00 |
| Sep 30, 2012 | -927,000.00 |
| Jun 30, 2012 | -1.15 Mn |
| Mar 31, 2012 | -1.41 Mn |
| Dec 31, 2011 | -1.63 Mn |
| Sep 30, 2011 | -1.82 Mn |
| Jun 30, 2011 | 294,000.00 |
| Mar 31, 2011 | -2.21 Mn |
| Dec 31, 2010 | -1.60 Mn |
| Sep 30, 2010 | -2.11 Mn |
| Jun 30, 2010 | -2.27 Mn |